Gyre Therapeutics Inc. (GYRE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $480.49M
Last updated: Nov 17, 2026 at 4:10 PM ET
Gyre Therapeutics Inc. (GYRE) Stock Chart
Gyre Therapeutics (GYRE) has a latest price of $4.56 on Nov 17, 2026, 50.1% below its 52-week high of $9.14. Its price fell 42.9% over the past 12 months. The month-end price fell 89.3% over the 10 years through Oct 2026, a compound annual decline of 20.0%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $112.32 in Apr 2018 and its lowest $1.89 in Apr 2022, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart GYRE with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for GYRE.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 36.2%, and over 6 months it fell 27.2%. The month-end price fell 32.3% over the 3 years through Oct 2026, a compound annual decline of 12.2%.
| Period | Change |
|---|---|
| 1 month | -25.1% |
| 3 months | -36.2% |
| 6 months | -27.2% |
| 12 months | -42.9% |
| 12 months, with dividends | -42.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -32.3% | -12.2% |
| 5 years | -64.9% | -18.9% |
| 10 years | -89.3% | -20.0% |
Price by Year
Its best calendar year was 2023, when the price rose 224.8%, and its weakest was 2021, when it fell 85.5%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $4.55 | -35.5% |
| 2025 | $7.06 | -41.7% |
| 2024 | $12.10 | -52.9% |
| 2023 | $25.69 | +224.8% |
| 2022 | $7.91 | +119.5% |
| 2021 | $3.60 | -85.5% |
| 2020 | $24.88 | -7.3% |
| 2019 | $26.85 | -13.7% |
| 2018 | $31.10 | -42.2% |
| 2017 | $53.77 | +39.9% |
Trading Range
The price is 26.4% below its 50-day average of $6.20 and 32.7% below its 200-day average of $6.77.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $4.56 | |
| 52-week high | $9.14 | -50.1% |
| 52-week low | $3.97 | +14.9% |
| 50-day average | $6.20 | -26.4% |
| 200-day average | $6.77 | -32.7% |
Price Risk
Over 3 years, its largest fall from a peak was 86.5%.
| Measure | Value |
|---|---|
| 1-year beta | 1.63 |
| Largest fall, 1 year | -54.2% |
| Largest fall, 3 years | -86.5% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About GYRE
What is GYRE's 1-year price change?
Gyre Therapeutics's price fell 42.9% over the past 12 months. With dividends included, the 12-month total return was -42.9%.
What is GYRE's 5-year price change?
Gyre Therapeutics's month-end price fell 64.9% over the 5 years through Oct 2026, a compound annual decline of 18.9%. These figures leave out dividends.
What is GYRE's 52-week high and low?
Gyre Therapeutics's 52-week high is $9.14 and its 52-week low is $3.97. Its latest price of $4.56 on Nov 17, 2026 is 50.1% below the high.
What is GYRE's beta?
Gyre Therapeutics's 1-year beta against the S&P 500 is 1.63, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 54.2%.
Is the GYRE chart free?
Yes. Advanced Charting for GYRE is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
GYRE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors